Menu
BRAERG was first founded in 2012 in the city of Sorocaba, in the São Paulo State, and differentiated itself as a private R&D company, operating in the following areas: Experimentation in biotechnology, pharmacology and diagnostic methodologies.
Process scheduling
Development of biochemical and pharmaceutical products
BRAERG underwent a strict examination by a German certifier (DQS of Brazil) so that its research methodology was recognized internationally, receiving the ISO 9001:2015 Certificate.
In 2014, BRAERG was selected along with EMBRAER and VALE to join the Innovation Platform of the Ministry of Science and Technology.
In 2015, invited by the Harvard Business Review Brazil, BRAERG was a panelist in its innovation forum on industry 4.0.
In 2016, the Getúlio Vargas Foundation (FGV) recognized BRAERG's activities as one of the 11 most promising business and scientific initiatives in Brazil.
TECHNOLOGIES DEVELOPED
• Acetic Acid
• Antibiotic
• 3G ethanol
• Polystyrene
• Phytotherapic
• Antibiotic
• 3G ethanol
• Polystyrene
• Phytotherapic
ACETIC ACID:
This was the first biotechnology developed by BRAERG. It is a methodology capable of transforming ethanol directly into glacial acetic acid with an industrially viable yield, using a consortium of enzyme overproducing microorganisms, resistant to high concentrations of ethanol combined with other physical-chemical parameters. It is used in the manufacture of raw materials applied in multiple segments of the chemical industry. Market: National: R$ 1 billion and International US$ 6.6 billion.
ANTIBIOTIC:
Also in 2016, BRAERG identified a substance capable of inhibiting the growth of contaminating bacteria amid solid and liquid culture media. In-house and interlaboratory analyzes performed demonstrated that the substance has high efficacy especially in inhibiting and combating 2 superbugs and 3 bacteria: Staphylococcus Aureus, Pseudomonas aeruginosa, Staphylococcus Epidermis, Streptococcus Pyogenes and Eschirichia Coli. Global market: US$ 40 billion.
ETHANOL 3G
The company developed a consortium of microorganisms that transforms lignocellulosic and/or starch material into ethanol. It is a disruptive technology that can be applied globally, as it can be used in several biomasses: cane, corn, potato, banana, sorghum, wood residues, etc. The final product is the same, however, the process does not generate environmental liabilities and can be used in existing plants. Market: National: R$ 14 billion and International R$ 100 billion.
POLYSTYRENE:
The process developed by BRAERG removes the pigments and additives present in the thermoplastic resins to be recycled, obtaining a colorless thermoplastic as a result, maintaining its characteristics, enabling new colorings as well as new applications, resulting in a significant increase in its market value. US$ 26 billion market.
PHYTOTHERAPIC:
The BRAERG patent describes a composition that has a healing, anti-inflammatory and antibiotic action. Specifically, it inhibits the growth of pathogenic microorganisms and accelerates the healing process. The composition of the extracts decreases the epidermis epithelization time, which consequently decreases the formation of fibers responsible for the appearance of scars, attenuating the wound marks. Market: National: US$ 412 MM and USA: 3.2 billion.
Patents
The highlight of BRAERG's scientific trajectory is the achievement of patents.
American patent grant.
European Union patent grant: United Kingdom, France, Germany, Italy, Ireland, Spain, Switzerland, Luxembourg, Monaco.
Brazilian patent grant.
Currently, BRAERG’s shareholders are exclusively dedicated to the monetization of their technologies developed over the years, and they share this know-how through BSA BIO.